Results 251 to 260 of about 77,584 (306)

The Immune Landscape of Acral Melanoma: From Basic to Clinical

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background Acral melanoma (AM) is an aggressive melanoma subtype with poor prognosis and limited response to immune checkpoint inhibitors (ICIs). Despite increasing research efforts, the mechanisms underlying therapeutic resistance remain incompletely understood.
Lihong Jiang, Zhaotian Zhang
wiley   +1 more source

In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAF^V600E lung adenocarcinoma. [PDF]

Cell Rep Med
Nokin MJ, Darbo E, Richard E, San José S, de Hita S, Prouzet-Mauleon V, Turcq B, Gerardelli L, Crake R, Velasco V, Koopmansch B, Lambert F, Xue JY, Sang B, Horne J, Ziemons E, Villanueva A, Blomme A, Herfs M, Cataldo D, Calvayrac O, Porporato P, Nadal E, Lito P, Jänne PA, Ricciuti B, Awad MM, Ambrogio C, Santamaría D, Bolero Consortium.   +29 more
europepmc   +1 more source

Contemporary Applications of Chemical Libraries for Drug Discovery and Methods for Their Synthesis

ChemistryEurope, Volume 4, Issue 5, May 2026.
Screening of chemical libraries has over the past decades become a cornerstone of drug discovery. Today, a broad range of chemical libraries exist but they are often not well described in terms of diversity. This review describes current efforts which aim to visualize chemical diversity in compound collections and discuss current trends in synthetic ...
Tobias N. Hansen, Nils J. V. Hansen
wiley   +1 more source

Emerging Neuroprotective Strategies: Unraveling the Potential of HDAC Inhibitors in Traumatic Brain Injury Management. [PDF]

Curr Neuropharmacol
Ye L, Li W, Tang X, Xu T, Wang G.
europepmc   +1 more source

Development of Potent Dual BET/HDAC Inhibitors via Pharmacophore Merging and Structure-Guided Optimization. [PDF]

ACS Chem Biol
Bauer N, Balourdas DI, Schneider JR, Zhang X, Berger LM, Berger BT, Schwalm MP, Klopp NA, Siveke JT, Knapp S, Joerger AC.   +10 more
europepmc   +1 more source

Underlying anti-cancer mechanisms of histone deacetylase (HDAC) inhibitors in tamoxifen-resistant breast cancer cells. [PDF]

Iran J Basic Med Sci
Wang L, Xu Y, Gao C.
europepmc   +1 more source

HDAC inhibitors target IRS4 to enhance anti‑AR therapy in AR‑positive triple‑negative breast cancer. [PDF]

Int J Oncol
He Y, Ma Y, Zhu Y, Zhang J, Zhao S, Zhang D, Xu D, Li Y, Tong Z, Zhao W.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Inside HDAC with HDAC inhibitors

European Journal of Medicinal Chemistry, 2010
Histone deacetylase inhibitors are a large group of diverse molecules intrinsically able to inhibit cell proliferation in various cancer cell lines. Their apoptotic effects have been linked to the modulation in the expression of several regulatory tumor suppressor genes caused by the modified status of histone acetylation, a key event in chromatin ...
Philippe Bertrand
openaire   +4 more sources